FY2016 Earnings Forecast for Sanofi (SNY) Issued By Jefferies Group
Sanofi (NYSE:SNY) – Investment analysts at Jefferies Group lowered their FY2016 EPS estimates for shares of Sanofi in a research note issued on Thursday. Jefferies Group analyst J. Holford now forecasts that the brokerage will earn $2.95 per share for the year, down from their prior forecast of $3.06. Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for Sanofi’s FY2017 earnings at $2.93 EPS, FY2018 earnings at $3.17 EPS, FY2019 earnings at $3.60 EPS and FY2020 earnings at $4.06 EPS.
Several other equities analysts have also commented on the company. Leerink Swann reissued a “buy” rating on shares of Sanofi in a research note on Sunday, October 9th. Piper Jaffray Cos. began coverage on Sanofi in a report on Friday, September 23rd. They set a “neutral” rating on the stock. JPMorgan Chase & Co. restated an “underweight” rating on shares of Sanofi in a report on Thursday, September 15th. BNP Paribas upgraded Sanofi from an “underperform” rating to a “neutral” rating in a report on Tuesday, September 13th. Finally, Berenberg Bank upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Thursday, September 8th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $60.50.
Sanofi (NYSE:SNY) traded up 0.08% during midday trading on Friday, reaching $37.76. 1,635,370 shares of the company traded hands. The firm has a 50-day moving average of $38.67 and a 200-day moving average of $40.40. The stock has a market capitalization of $97.19 billion, a P/E ratio of 21.08 and a beta of 0.98. Sanofi has a 1-year low of $37.20 and a 1-year high of $51.88.
Several hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. increased its position in Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock valued at $144,000 after buying an additional 1,500 shares during the last quarter. Signaturefd LLC increased its position in Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock valued at $146,000 after buying an additional 490 shares during the last quarter. JFS Wealth Advisors LLC increased its position in Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock valued at $166,000 after buying an additional 134 shares during the last quarter. BlackRock Institutional Trust Company N.A. bought a new position in Sanofi during the first quarter valued at $175,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in Sanofi during the second quarter valued at $205,000. 9.42% of the stock is owned by institutional investors and hedge funds.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.